文献速递基础与转化研究新药、器械与细胞基因治疗研发

肺动脉高压的发病机制与临床管理

Pulmonary arterial hypertension: pathogenesis and clinical management.
PubMed 文献 · BMJ · 2018-03-14

本文综述肺动脉高压(PH)及肺动脉高压(PAH)的流行病学、发病机制、诊断与治疗。PAH 以肺血管收缩、重构和硬化导致右心室后负荷增加为特征,涉及 BMPR2 突变、表观遗传失调、线粒体代谢异常及炎症免疫机制。靶向药物改善功能与血流动力学,但未证实降低死亡率,五年死亡率约 50%。

要点

  • PAH 由血管收缩、重构和硬化共同导致肺血管阻力升高。
  • BMPR2 突变显著增加遗传性 PAH 风险,表观遗传和代谢异常参与发病。
  • 靶向药物改善功能与血流动力学,但未证实降低死亡率,五年死亡率约 50%。

核心结论

  • PAH 靶向治疗改善功能容量和血流动力学并减少住院,但未证实降低死亡率,五年死亡率约 50%。

研究设计与样本

  • 本文为综述,总结 PAH 的流行病学、发病机制、诊断和治疗。

主要发现

  • PAH 中肺血管受血管收缩动态阻塞、不良重构结构阻塞及纤维化硬化导致顺应性下降。
  • BMPR2 基因突变显著增加遗传性 PAH 风险。
  • DNA 甲基化、组蛋白乙酰化和 microRNA 的表观遗传失调参与发病。
  • BMP 信号异常和表观遗传失调部分通过诱导 Warburg 线粒体代谢状态促进细胞增殖。
  • 细胞因子、细胞免疫和自身抗体变化提示 PAH 部分为自身免疫炎症性疾病。

关键数值与推荐

  • 肺动脉高压定义为静息平均肺动脉压≥25 mm Hg。
  • PAH 靶向治疗包括前列腺素类、磷酸二酯酶-5 抑制剂、内皮素受体拮抗剂和可溶性鸟苷酸环化酶刺激剂,单用或联用。

临床怎么用

  • PAH 患者可用靶向药物单药或联合治疗以改善功能容量和血流动力学并减少住院。
  • 需关注右心室功能,右心室适应不良改变如缺血和纤维化可导致右心衰竭。

局限性

  • 靶向血管扩张剂未针对 PAH 发病关键特征,且未证实降低死亡率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pulmonary hypertension is defined as a resting mean pulmonary artery pressure of 25 mm Hg or above. This review deals with pulmonary arterial hypertension (PAH), a type of pulmonary hypertension that primarily affects the pulmonary vasculature. In PAH, the pulmonary vasculature is dynamically obstructed by vasoconstriction, structurally obstructed by adverse vascular remodeling, and pathologically non-compliant as a result of vascular fibrosis and stiffening. Many cell types are abnormal in PAH, including vascular cells (endothelial cells, smooth muscle cells, and fibroblasts) and inflammatory cells. Progress has been made in identifying the causes of PAH and approving new drug therapies. A cancer-like increase in cell proliferation and resistance to apoptosis reflects acquired abnormalities of mitochondrial metabolism and dynamics. Mutations in the type II bone morphogenetic protein receptor (BMPR2) gene dramatically increase the risk of developing heritable PAH. Epigenetic dysregulation of DNA methylation, histone acetylation, and microRNAs also contributes to disease pathogenesis. Aberrant bone morphogenetic protein signaling and epigenetic dysregulation in PAH promote cell proliferation in part through induction of a Warburg mitochondrial-metabolic state of uncoupled glycolysis. Complex changes in cytokines (interleukins and tumor necrosis factor), cellular immunity (T lymphocytes, natural killer cells, macrophages), and autoantibodies suggest that PAH is, in part, an autoimmune, inflammatory disease. Obstructive pulmonary vascular remodeling in PAH increases right ventricular afterload causing right ventricular hypertrophy. In some patients, maladaptive changes in the right ventricle, including ischemia and fibrosis, reduce right ventricular function and cause right ventricular failure. Patients with PAH have dyspnea, reduced exercise capacity, exertional syncope, and premature death from right ventricular failure. PAH targeted therapies (prostaglandins, phosphodiesterase-5 inhibitors, endothelin receptor antagonists, and soluble guanylate cyclase stimulators), used alone or in combination, improve functional capacity and hemodynamics and reduce hospital admissions. However, these vasodilators do not target key features of PAH pathogenesis and have not been shown to reduce mortality, which remains about 50% at five years. This review summarizes the epidemiology, pathogenesis, diagnosis, and treatment of PAH.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Thenappan T, Ormiston ML, Ryan JJ, et al. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018. PMID: 29540357. doi:10.1136/bmj.j5492

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。